Cargando…

What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Over the past decade, immune checkpoint inhibitors (ICIs) have transformed the management of multiple malignancies including lung cancer. However, the optimal use of these agents in terms of duration, dose and administration frequency remains unknown. Focusing on anti-PD1 agents nivolumab and pembro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuah, Chii Yang, Monfries, Robert, Quartagno, Matteo, Seckl, Michael J., Ghorani, Ehsan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638879/ https://www.ncbi.nlm.nih.gov/pubmed/37954230 http://dx.doi.org/10.1177/17588359231210271

Ejemplares similares

Emergency craniotomy: a life-saving procedure as part of multi-modal therapy of GTN
por: Ghorani, Ehsan, et al.
Publicado: (2022)

REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers
por: Merrick, Sophie, et al.
Publicado: (2023)

Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma
por: Tachiki, Lisa May Ling, et al.
Publicado: (2023)

The DURATIONS randomised trial design: Estimation targets, analysis methods and operating characteristics
por: Quartagno, Matteo, et al.
Publicado: (2020)

Rethinking non-inferiority: a practical trial design for optimising treatment duration
por: Quartagno, Matteo, et al.
Publicado: (2018)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
por: Yin, Jiaxin, et al.
Publicado: (2022)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
por: Silverman, Stuart L.
Publicado: (2010)

The Importance of Dose, Frequency and Duration of Vitamin D Supplementation for Plasma 25-Hydroxyvitamin D
por: Chao, Yi-Sheng, et al.
Publicado: (2013)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Considerations for the Optimal Timing, Duration, Frequency, and Length of an Intermittent Fasting Regimen for Health Improvement
por: Horne, Benjamin D.
Publicado: (2020)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Multiple imputation for discrete data: Evaluation of the joint latent normal model
por: Quartagno, Matteo, et al.
Publicado: (2019)

Substantive model compatible multilevel multiple imputation: A joint modeling approach
por: Quartagno, Matteo, et al.
Publicado: (2022)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
por: Fujita, Kohei, et al.
Publicado: (2019)

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States
por: Fonseca, Rafael, et al.
Publicado: (2023)

What is the optimal duration of the TILT after administration of 0.4 mg nitroglycerin spray?
por: Glockler, Antonia, et al.
Publicado: (2020)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Effects of aerosolized citric acid–radio frequency as a pretreatment on hot‐air drying characteristics of banana
por: Ghorani, Reza, et al.
Publicado: (2021)

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
por: You, Wei, et al.
Publicado: (2018)

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
por: Zhang, Pei, et al.
Publicado: (2022)

The Impact of Attention on Judgments of Frequency and Duration
por: Winkler, Isabell, et al.
Publicado: (2015)

Nonstationary Temperature-Duration-Frequency curves
por: Ouarda, Taha B. M. J., et al.
Publicado: (2018)

PB2003: REAL-WORLD DURATION OF USE AND DOSING FREQUENCY OF DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA IN THE U.S.
por: Fonseca, R., et al.
Publicado: (2022)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

The optimal duration of anti-tuberculous therapy before pericardiectomy in constrictive tuberculous pericarditis
por: Fang, Likui, et al.
Publicado: (2021)

Neuronal characteristics of small-cell lung cancer
por: Onganer, P U, et al.
Publicado: (2005)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
por: Papadaki, Maria A, et al.
Publicado: (2020)

Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer
por: Jiang, Qi, et al.
Publicado: (2017)

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
por: Sui, Hongshu, et al.
Publicado: (2018)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
por: Kong, Yuehong, et al.
Publicado: (2021)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies
por: Puri, Sonam, et al.
Publicado: (2020)

Timing, optimal dose and intake duration of dietary supplements with evidence-based use in sports nutrition
por: Naderi, Alireza, et al.
Publicado: (2016)

Optimal dose and duration of enteral erythromycin as a prokinetic: A surgical intensive care experience
por: Shaikh, Nissar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1t338dpbhdi9n191n6b674mrb4